Sosei Group Corporation
4F Ichiban-cho FS Building
8 Ichiban-cho, Chiyoda-ku
46 articles with Sosei Group Corporation
Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership
Collaboration combines Sosei Heptares' GPCR-focused StaR® and structure-based drug design capabilities with Takeda's discovery, development and therapeutic area expertise
Sosei Group Corporation inked a strategic multi-target partnership with Takeda Pharmaceutical to find, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor targets. The initial focus will be on gastrointestinal targets.
Collaboration aims to discover and develop novel medicines that modulate G protein-coupled receptor (GPCR) targets across a range of diseases
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
MiNA Therapeutics remains on track with current development plans for small activating RNA medicines including clinical development of MTL-CEBPA drug candidate
Allergan and its development partner Sosei Group have voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.
Sosei Group Corporation announces that Mr. Andrew Oakley, Executive Vice President and CFO, has resigned from the Company.
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
Sosei Confirms New Data Demonstrating AZD4635, a Novel A2A Receptor Antagonist, Induces Anti-Tumor Immunity Alone and in Combination With Anti-PD-L1 in Preclinical Models
New data presented at 2018 AACR Meeting
Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches
Sosei Group announced that it has regained worldwide rights from Teva Pharmaceutical Industries Limited to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches.
The first patient has been dosed in an expansion cohort in the Phase 1b segment of the Phase 1 study in advanced solid tumours.
Sosei today announced that it will be restating selected financial statements previously issued by the Company.
Entry on the day will commence from 09:30 a.m.
Dr. Marshall will leave Sosei at the end of February 2018.
Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients With Dementia With Lewy Bodies (DLB)
Initially, Sosei will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018.
Sosei Group Corporation Subsidiaries Heptares And Jitsubo To Develop Novel GPCR-Targeting Peptide Candidates For Severe Gastro-Intestinal Disorders
Sosei Group Corporation Subsidiary Heptares Awarded $5.5 Million Research & Development Grant From National Institute on Drug Abuse (NIDA)
Sosei Group Corporation Announces Positive Results For Ultibro® And Seebri® Presented At ERS 2014, And Promotion Agreement With Pfizer Inc. In The UK